StockData
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)

Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –

Ascendis Pharma A/S operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ascendis Pharma A/S's operating income for the twelve months ending Jun 30, 2026 was €266.17M. For fiscal 2025 it was -€136.27M. The highest annual figure on record is -€41.83M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€136.27M–
FY2024Dec 31, 2024-€278.76M–
FY2023Dec 31, 2023-€455.54M–
FY2022Dec 31, 2022-€561.81M–
FY2021Dec 31, 2021-€451.79M–
FY2020Dec 31, 2020-€330.62M–
FY2019Dec 31, 2019-€226.72M–
FY2018Dec 31, 2018-€154.76M–
FY2017Dec 31, 2017-€111.54M–
FY2016Dec 31, 2016-€72.92M–
FY2015Dec 31, 2015-€41.83M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€220.47M–
Q1 FY2026Mar 31, 2026€24.81M–
Q4 FY2025Dec 31, 2025€9.90M+2483.8%
Q3 FY2025Sep 30, 2025€11.00M–
Q2 FY2025Jun 30, 2025-€52.95M–
Q1 FY2025Mar 31, 2025-€104.21M–
Q4 FY2024Dec 31, 2024€383.00K–
Q3 FY2024Sep 30, 2024-€96.74M–
Q2 FY2024Jun 30, 2024-€133.26M–
Q1 FY2024Mar 31, 2024-€49.15M–
Q4 FY2023Dec 31, 2023-€36.61M–
Q3 FY2023Sep 30, 2023-€134.41M–
Q2 FY2023Jun 30, 2023-€140.84M–
Q1 FY2023Mar 31, 2023-€143.69M–
Q4 FY2022Dec 31, 2022-€147.39M–
Q3 FY2022Sep 30, 2022-€144.51M–
Q2 FY2022Jun 30, 2022-€141.89M–
Q1 FY2022Mar 31, 2022-€128.03M–
Q4 FY2021Dec 31, 2021-€112.58M–
Q3 FY2021Sep 30, 2021-€96.93M–
Q2 FY2021Jun 30, 2021-€117.63M–
Q1 FY2021Mar 31, 2021-€124.65M–
Q4 FY2020Dec 31, 2020-€95.64M–
Q3 FY2020Sep 30, 2020-€78.83M–
Q2 FY2020Jun 30, 2020-€82.95M–
Q1 FY2020Mar 31, 2020-€73.21M–
Q4 FY2019Dec 31, 2019-€64.85M–
Q3 FY2019Sep 30, 2019-€54.02M–
Q2 FY2019Jun 30, 2019-€51.58M–
Q1 FY2019Mar 31, 2019-€56.28M–
Q4 FY2018Dec 31, 2018-€35.85M–
Q3 FY2018Sep 30, 2018-€38.29M–
Q2 FY2018Jun 30, 2018-€45.44M–
Q1 FY2018Mar 31, 2018-€35.17M–
Q4 FY2017Dec 31, 2017-€31.84M–
Q3 FY2017Sep 30, 2017-€31.47M–
Q2 FY2017Jun 30, 2017-€24.67M–
Q1 FY2017Mar 31, 2017-€23.56M–

More Ascendis Pharma A/S figures

See a number that looks wrong?